stockrow
Saturday 7 November 2026
Export MTNB’s income statement to Excel — free account
Matinas Biopharma Holdings, Inc.
MTNB Healthcare Biotechnology
Matinas Biopharma Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.1 million, down 65.6% from fiscal 2022.
- EPS
- +79.6%
- Free cash flow
- +9.15%
- Total debt
- −54.5%
Quarter to June 2026, against a year earlier
1.19
0.03
+2.59%
Follow MTNB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (154.28%) | (241.67%) | (176.54%) | (157.24%) |
+8 more TTM periods Free account |
|
| (98.53%) | (125.39%) | (110.46%) | (115.51%) | ||
ROIC |
(419.27%) | (750.22%) | (553.44%) | (876.71%) | |
Return on Tangible Assets |
3,530.92% | (1,357.68%) | (398.65%) | (405.29%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(15.02) | (15.46) | (18.33) | (24.57) | |
Free Cash Flow |
(6.42) | (6.60) | (6.69) | (8.91) | |
Capital Expenditures |
— | — | 0.32 | 0.10 | |
| Other line items | |||||
Cash ROIC |
(245.41%) | (120.64%) | (75.33%) | (74.52%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.88 | 0.59 | 0.64 | 0.52 | |
Depreciation/Fixed assets |
0.00 | 2.91 | 3.30 | 3.89 | |
Capex/Depreciation |
0.00 | 0.00 | 0.70 | 0.17 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(15.02) | (15.46) | (19.20) | (24.85) | |
Capex per Share |
0.00 | 0.00 | 0.87 | 0.28 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026